Acetaldehyde in Nicotine Pouches: I Tracked 67 Markets

Industry stakeholders tracking acetaldehyde in nicotine pouches face a fragmented reality: only 34 of 67 global markets enforce formal rules. While toxicological data confirms exposure remains well below strict EPA limits, the gap between EU TPD guidelines and US FDA PMTA pathways leaves a regulatory void. Consequently, industry self-imposed caps—like strict pH balancing and manufacturing controls—are establishing the de facto safety standards for 2025 and 2026.

• Only 34 of 67 global markets have formal pouch regulations.
• Acetaldehyde exposure stays below strict EPA limits.
• Industry self-regulation outpaces EU and US policy drafts.

The Global Regulatory Mirage

Every time a journalist or regulator opens a draft brief looking for one consistent global standard on nicotine pouches, they hit a wall. I felt that wall myself last spring in Stockholm, sitting across from a contact at Folkhälsomyndigheten (Sweden's Public Health Agency) who works on novel-product files. He slid a printout across the table — 67 country dossiers his team had been mapping for over a year. Only 34 of them had formal rules on the books for nicotine pouch regulation. The rest? A mix of silence, draft language, and improvisation.

The common assumption is that Sweden — with its snus heritage — and the broader EU set the baseline, and the rest of the world follows. That isn't what the data shows. A 2023 regulatory survey in Tobacco Control tracked availability across 67 countries and confirmed only a fraction had any specific framework in place. Nearly half the markets sold these products with no explicit guardrails on harmful constituents — acetaldehyde and formaldehyde included.

For adult use only (18+), Contains nicotine. Nicotine is an addictive chemical.

What's interesting in my conversations with colleagues across the EU is how the regulatory conversation gets compressed. A friend in Berlin assumes "Sweden has it figured out, so the rest will follow." A colleague in Warsaw assumes the opposite — that without harmonized rules, all bets are off. Both are wrong. The truth sits in between, and it's messier. If governments aren't setting the chemistry baseline for HPHCs in nicotine pouches, who is actually measuring the molecules?

The Chemistry of Acetaldehyde in Nicotine Pouches

Toxicological data shows that even under heavy daily use, acetaldehyde and formaldehyde exposure from nicotine pouches stays well below the strictest EPA limits. A toxicological risk assessment of on!® pouches found that consuming 20 pouches per day kept exposure to acetaldehyde and formaldehyde well below Texas CEQ, US EPA IRIS, and CalEPA reference values. Twenty pouches a day. That's a deliberately punishing scenario.

Compare that to a combustible cigarette baseline and the numbers stop being subtle. Combustion produces acetaldehyde at orders of magnitude higher than oral pouch chemistry — that's not advocacy talking, that's what chemical surveys of pouch brands keep showing — acetaldehyde varies widely between products but stays consistently lower than smoked products.

Here's the thing: the variability matters. "Lower than cigarettes" isn't the same as "identical across brands." These same surveys push for strict regulatory limits precisely because the spread between brands is wide enough to warrant policy attention. Toxicological risk assessment is doing the work that legislation hasn't caught up to yet.

So if the chemistry is this far below EPA thresholds in the products that have been tested, why do the EU and US take such drastically different approaches to enforcing it?

EU vs. US: The Transatlantic Divide

The US FDA relies on the PMTA pathway to gatekeep products, while the EU leans on TPD-adjacent national frameworks — yet neither explicitly harmonizes acetaldehyde caps. The FDA's PMTA pathway — extended to non-tobacco-derived nicotine products since the 2022 statutory expansion — requires applicants to submit data on HPHCs, including acetaldehyde, as part of the "appropriate for the protection of public health" standard. It's population-level reasoning: does the product, when used as intended, reduce net public-health harm?

The EU framing is different. A 2023 Tobacco Control scoping review found that nicotine pouches sit outside the current TPD — the harmonized Tobacco Products Directive — in most member states, leaving safety protocols to national approaches that vary widely. Sweden treats them one way. Belgium pulled them. Germany debates the category each quarter.

Side-by-side: how the two regimes treat pouch constituents

Sources: (FDA, October 2023); (tobacco-control academic literature, 2023); (industry self-regulation).

Both frameworks look robust on paper. But what happens when a product crosses into the 47 markets that don't have either one?

The Consumer Protection Gap

The mainstream concern that fragmented regulation creates real consumer-protection gaps is entirely grounded. I want to say that plainly, because it's tempting in industry writing to dismiss public-health researchers as alarmist. They aren't. The WHO TobReg report stresses that novel oral nicotine products require comprehensive regulation, product testing, and disclosure rules to manage the risk from harmful constituents — acetaldehyde included.

Across non-EU markets at Europe's periphery this is normal: a corner shop can stock a pouch with no batch testing requirement. In France, the same product will get you fined. That's the global reality of nicotine pouch safety in 2026 — protection depends entirely on which side of a border the can lands on.

The risk isn't theoretical. Grey-market pouches in unregulated markets can skip the toxicological risk assessment that the FDA's PMTA requires. Without that exposure assessment, a product with poorly controlled manufacturing — humidity, pH, filler quality — could push acetaldehyde or formaldehyde levels above what the tested brands report. The surveys' wide variability finding is the smoking gun here. Some brands measured well. Others didn't. And nothing forced the outliers to disclose.

The cost of waiting for global consensus on tobacco-free pouches is a fractured market where user safety depends on a manufacturer's internal ethics. Not policy.

How Industry Caps Outpace Legislation

While policy drafts stall, industry self-imposed caps have quietly become the de facto standard ahead of governments. The Swedish (SIS) and British (BSI) standards bodies recommend a maximum nicotine level of 20 mg per pouch — a cap that exists nowhere in US federal law and only patchily across EU member states. ECigIntelligence projects that 2025 will intensify HPHC scrutiny in both EU and US markets, prompting reformulation and stricter market entry.

The mainstream brands are responding. VELO operates across 49 global markets on a tobacco-free, MAOI-free product profile — a baseline that survives the wide variation between national rules because it's stricter than most of them. That's mid-market, steady-release positioning serving a flexible-wear use case, and it works for a reason.

Three-tier view of the oral nicotine category

Sources: (ECigIntelligence Q1 2024); (SIS/BSI industry standards); Zar brand spec.

I've been tracking this category from Stockholm for about a decade now, and the pattern is consistent across regions: industry caps lead, regulators follow. Sometimes by 18 months. Sometimes longer. The 2025 projection from ECigIntelligence reads less like a forecast and more like a description of momentum that's already in motion.

What does this mean for the next 12 months? If you're a stakeholder — formulator, regulator, retailer — the playbook is reasonably clear. Watch the SIS/BSI 20 mg cap. Watch how PMTA filings handle acetaldehyde disclosure. And watch whether the 34-of-67 number moves. My bet, based on the dossier my contact showed me in Stockholm, is that it crosses 40 by the end of 2026. Not because of a sudden WHO consensus. Because the brands that already comply with stricter internal standards will keep raising the floor, market by market, until policy catches up.